PDF(Pubmed)
Abstract：
Significant clinical response was obtained in a patient with stage IV colorectal cancer (CRC) following combination therapy involving capecitabine and adoptive cell transfer therapy. She had laparoscopic lower anterior resection and left liver metastatic carcinoma resecting in 20th, February, 2017. Capecitabine was used to further treatment for an unresectable hepatic metastasis. The serum level of carcinoembryonic antigen (CEA) was increased significantly after dropped temporarily. Since then, the patient took the adoptive cell transfer therapy at the same time. αβT cells and NK cells were injected intravenously into the patient. After the first transfusion with αβT cells, the tumor biomarker, CEA, dropped obviously from 14.7 to 6.1 ng/mL. And it came to 1.9 ng/mL after four times treatment, which was back into normal range (<5 ng/mL). Flow cytometry (FCM) was used to reveal the detailed immunological status of this patient before and after adoptive cell transfer therapy. With 19-month follow-up, neither recurrence or complication was founded. Combination therapy involving adoptive immunotherapy and capecitabine may be the potential method for advanced CRC with less complication.
摘要：
在涉及卡培他滨和过继性细胞转移疗法的联合疗法后，患有IV期结直肠癌（CRC）的患者获得了显着的临床反应。20日行腹腔镜下前切除术，左肝转移癌切除，二月,2017.卡培他滨用于进一步治疗不可切除的肝转移。血清癌胚抗原（CEA）水平暂时下降后明显升高。从那以后,患者同时接受过继性细胞转移治疗。将αβT细胞和NK细胞静脉注射到患者体内。首次输注αβT细胞后，肿瘤生物标志物，CEA,从14.7ng/mL明显下降到6.1ng/mL。经过四次治疗后达到1.9纳克/毫升，回到正常范围（<5ng/mL）。流式细胞术（FCM）用于揭示该患者在过继细胞转移治疗前后的详细免疫状态。经过19个月的随访，没有发现复发或并发症.涉及过继免疫疗法和卡培他滨的联合治疗可能是晚期CRC并发症少的潜在方法。
